Aurisco(SH:605116) Soochow Securities·2025-04-28 05:01Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights significant achievements in the company's integrated transformation, particularly in the growth of peptide and oligonucleotide segments [7] - The company reported a revenue of 1.476 billion yuan in 2024, representing a year-on-year increase of 16.89%, and a net profit attributable to shareholders of 354.79 million yuan, up 22.59% [7] - The report anticipates continued growth in the raw material drug sector, with a focus on the expansion of peptide and oligonucleotide products as new growth drivers [7] Financial Summary - Total revenue projections for the company are as follows: 1.263 billion yuan in 2023, 1.476 billion yuan in 2024, 1.842 billion yuan in 2025, 2.158 billion yuan in 2026, and 2.750 billion yuan in 2027, with respective year-on-year growth rates of 25.24%, 16.89%, 24.79%, 17.19%, and 27.42% [1][8] - The net profit attributable to shareholders is projected to be 289.42 million yuan in 2023, 354.79 million yuan in 2024, 477.42 million yuan in 2025, 597.50 million yuan in 2026, and 731.69 million yuan in 2027, with year-on-year growth rates of 37.19%, 22.59%, 34.56%, 25.15%, and 22.46% [1][8] - The report provides a P/E ratio forecast of 29.89 for 2023, 24.39 for 2024, 18.12 for 2025, 14.48 for 2026, and 11.82 for 2027 [1][8]